Pioneer advance in oncological immunotherapy
Russia is positioned at the forefront of oncological research with the development of a therapeutic vaccine based on messenger RNA (mRNA) technology, whose clinical trial in humans is scheduled to begin in 2025. As reported by the Russian Embassy in Mexico through an official statement, this treatment represents a milestone in personalized medicine against cancer.
Technology and mechanism of action
The Gamaleya National Center for Epidemiological Research and Microbiology, recognized for developing the Sputnik V vaccine against COVID-19, leads the project. The vaccine uses an mRNA platform similar to that used in pandemic immunizations, but adapted to train the immune system to identify and selectively destroy tumor cells. This approach minimizes damage to healthy tissues and reduces adverse effects compared to conventional chemotherapies.
Currently in the preclinical phase with animal models, researchers highlight its potential to revolutionize therapeutic protocols. Alexander Gintsburg, director of Gamaleya, stated in 2024 that the vaccine demonstrated preclinical efficacy against multiple variants of cancer.
Accessibility and projections
The Russian government estimates an approximate cost of 3,000 USD per dose, although it will guarantee its free distribution to Russian citizens. If it passes clinical trials, this therapy could become a viable alternative for patients with cancer in early and advanced stages.
Are you interested in medical innovation? Share this scientific advance on your social networks and discover more content about biotechnology applied to oncology on our platform.




